Journal of Clinical & Medical Genomics

Fang Jing

Publications

• Review Article
  Thrombosis Therapy: Focus on Antiplatelet Agents
  Author(s): Fang Jing and Wei ZhangFang Jing and Wei Zhang
  
  Platelet adhesion, activation and aggregation to the injured vessel wall are crucially involved in the pathogenesis of thrombus formation. Agents in theory thwarting these phases would have significant clinical value. The current antiplatelet drugs used in daily clinical practice include COX-1 inhibitor aspirin, ADP P2Y12 receptor antagonist clopidogrel, and the GPIIb-IIIa antagonists (abciximab, eptifibatide and tirofiban). However, confined curative ratio along with unforeseen bleeding risk remains a major puzzle of antiplatelet therapy. With advances in understanding of the molecular basis of platelet in thrombosis, newer antiplatelet agents that targets different stage of thrombus formation have been recently developed, mostly including agents targeting platelet adhesion (GPIV, vWF), activation (GPVI, P2Y12, TPα, PAR1, phosphodiesterase, cyclooxygenase),.. Read More»
  DOI: 10.4172/2332-0672.1000103

  Abstract PDF